Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
While no consistent differences in HDL functions were observed ex vivo, people without vascular complications had higher levels of HDL-associated paraoxonase 1 (PON1), an enzyme that inhibits atherosclerosis in animal models.
|
31597668 |
2020 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Paraoxonase-1 (PON-1) is a high-density lipoprotein (HDL)-associated hydrolase that appears to have a protective action against atherosclerosis.
|
31626928 |
2020 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Paraoxonase 1 (PON1) is important in the development of atherosclerosis, and it has become the subject of intensive research.
|
31626760 |
2020 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
PON1 inhibits the oxidation of HDL and low density lipoprotein (LDL), and is involved in the pathogenesis of a variety of diseases including atherosclerosis.
|
30044465 |
2019 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Paraoxonase 1 Activity, Polymorphism and Atherosclerosis Risk Factors in Patients Undergoing Coronary Artery Surgery.
|
30935088 |
2019 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The behaviour of some antihypertension drugs on human serum paraoxonase-1: an important protector enzyme against atherosclerosis.
|
31347707 |
2019 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> Paraoxonase 1 (PON1: EC 3.1.8.1) is a vital antioxidant enzyme against mainly atherosclerosis and many other diseases associated with oxidative stress.
|
29741961 |
2019 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
All associations found could indicate the relationship between PON lactonase activity and the development of atherosclerosis.
|
30681756 |
2019 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
PON1 activators, compounds 10, 13 and 17 stand out as potential drug candidates for further antioxidant studies and these compounds can be investigated for their therapeutic effects in many disorders such as atherosclerosis, diabetes mellitus, obesity, chronic liver inflammation and many more.
|
29773067 |
2019 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of paraoxonase-1 L55M and Q192R polymorphisms with PCOS risk and potential risk factors for atherosclerosis.
|
30900463 |
2019 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The role of PON1 in cancer is also covered, as risk factors and mechanisms underlying both atherosclerosis and cancer share common features.
|
31400246 |
2019 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this review is to summarize the characteristics of PON-1, its interactions with drugs and its role in atherosclerosis and especially its relationship with carotid artery disease.
|
29189170 |
2019 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mice, double-knockout (DKO) for ApoE (major cholesterol carrier in brain) and PON1 (paroxonase1, reduces oxidative stress), showed severe age-dependent atherosclerosis of the arteries carrying blood to the brain even on normal diet.
|
30714958 |
2019 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ticagrelor induces paraoxonase-1 (PON1) and better protects hypercholesterolemic mice against atherosclerosis compared to clopidogrel.
|
31242230 |
2019 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study showed that altered HDL subclasses distribution, changed PON1 activities on different HDL subclasses as well as diminished anti-oxidative protection could be important factors in atherosclerosis development in CKD and ESRD patients.
|
30130521 |
2018 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our aim was to investigate serum SAA, PON1, and apolipoprotein levels as indicators of subclinical atherosclerosis in patients with nonfunctioning AI (NFAI) and SH.
|
30031631 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Paraoxonase-1 (PON-1) may protect against atherosclerotic cardiovascular disease development by attenuating oxidative stress.
|
29171874 |
2018 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The polymorphisms of ApoE and paraoxonase (PON1) L55M (Met < Leu) allele genes lead to disorders in lipid metabolism and are related to atherosclerosis.
|
29273831 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Paraoxonase-1 (PON1) is the antioxidant marker of high-density lipoproteins protecting against atherosclerosis and coronary artery disease (CAD) phenotype.
|
29118461 |
2017 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PON1 activity is lower in patients with atherosclerosis and in inflammatory diseases.
|
28376720 |
2017 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pro-oxidant effects produced by metals can be mitigated by paraoxonase 1 (PON1), an antioxidant enzyme known to prevent cardiovascular disease and atherosclerosis.
|
28477577 |
2017 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In sum, these findings allowed us to propose serum levels of anti-PON1 and anti-HDL antibodies as potential early biomarkers of endothelial damage and premature atherosclerosis in SLE, thus constituting useful therapeutic targets for the prevention of future CVD in these patients.
|
29044294 |
2017 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sonographic evaluation of atherosclerosis burden in carotid arteries of ischemic stroke patients and its relation to paraoxonase 1 and 2, MTHFR and AT1R genetic variants.
|
28566152 |
2017 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PON genetic polymorphisms contribute to susceptibility/protection from atherosclerosis-related diseases.
|
27771368 |
2017 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
PON1 acts as antioxidant preventing low-density lipoprotein (LDL) oxidation, a process considered critical in the initiation and progression of atherosclerosis.
|
28223025 |
2017 |